drugset / Trial / NCT01002703
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2
Unknown
50 enrolled
University of Leipzig
Amgen · collabCelgene Corporation · collabMundipharma Pte Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 60 mg/m2 | — |
| Subject | Bendamustine | Small molecule | 75 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Prednisone | Other / unclassified | 100 mg | — |